Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

May

Today In Oncology

AACR Cancer Disparities Progress Report 2024 Highlights Ongoing Health Inequities Experienced by Racial and Ethnic Minorities

Previously Untreated Mantle Cell Lymphoma Ibrutinib, Immunochemotherapy, and ASCT

Marker for Distinguishing Renal Cell Carcinoma From Benign Renal Masses

FDA Approves HPV Self-Collection Solution

Disparities in Melanoma Outcomes Among Black Patients

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos